Posted by & filed under Company Analysis, Governments & Regulators, Growth & Valuation, Industry Analysis, Personal Finance.

Description: A COVID-19 vaccine from GlaxoSmithKline Plc and Canada’s Medicago Inc. demonstrated 71 per cent efficacy against multiple variants of the disease in a positive outcome for the pandemic latecomers.

Source: – video report

Date: Dec 07, 2021


Questions for discussion:

  • What are the advantages of this new technology?
  • Do you think this product can compete against offerings from giants like Pfizer?
  • How should investors treat this announcement, in your opinion?

Leave a Reply

Your email address will not be published. Required fields are marked *